Lead sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
9 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
9
Trials led
4
Active
2,130
Total enrollment
7
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
2
Phase 1/2
1
Phase 2
1
Phase 3
5
Trials by status
Recruiting
3
Active, not recruiting
1
Completed
5
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or ObesityBMI 24-28Ph 3Completed664
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DMBMI 20-35Ph 3Completed623
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM PatientsBMI 20-35Ph 3Completed211
A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)BMI ≥30Ph 2Active, not recruiting163
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure TherapyBMI ≥28Ph 3Recruiting140
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure TherapyBMI ≥28Ph 3Recruiting140
A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or ObesityBMI 24-35Ph 1/2Recruiting84
A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or DigoxinBMI 20-30Ph 1Completed57